| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.54▼ | 1.51▲ | 1.51▲ | 1.63▼ | 1.38▲ |
| MA10 | 1.52▼ | 1.52▲ | 1.53▼ | 1.48▲ | 1.35▲ |
| MA20 | 1.51▲ | 1.53▼ | 1.57▼ | 1.41▲ | 1.28▲ |
| MA50 | 1.53▼ | 1.61▼ | 1.54▼ | 1.36▲ | 3.94▼ |
| MA100 | 1.58▼ | 1.53▼ | 1.45▲ | 1.32▲ | 5.20▼ |
| MA200 | 1.68▼ | 1.44▲ | 1.38▲ | 3.27▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.003▲ | -0.011▼ | 0.024▲ | 0.216▲ |
| RSI | 48.581▼ | 44.437▼ | 43.655▼ | 56.533▲ | 37.981▼ |
| STOCH | 88.889▲ | 30.523 | 36.550 | 24.951 | 43.699 |
| WILL %R | -50.000 | -52.941 | -76.471▼ | -83.942▼ | -75.658▼ |
| CCI | 29.083 | 37.393 | -30.657 | 25.092 | 399.197▲ |
|
Thursday, August 14, 2025 06:40 AM
Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is ...
|
|
Thursday, August 14, 2025 06:40 AM
Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $8 from $9 and keeps an Outperform rating on the shares following Q2 results. The firm notes Phase 1 trial of ACR-2316 is ...
|
|
Wednesday, August 13, 2025 03:07 PM
Acrivon Therapeutics focuses on developing targeted cancer therapies using its proprietary AP3 platform, which is a proteomics-based technology. The AP3 platform analyzes proteins inside tumor cells ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 12/09/25 | 1.55 | 1.57 | 1.46 | 1.52 | 884,044 |
| 11/09/25 | 1.62 | 1.66 | 1.50 | 1.55 | 1,072,069 |
| 10/09/25 | 1.62 | 1.72 | 1.60 | 1.63 | 867,792 |
| 09/09/25 | 1.56 | 1.86 | 1.55 | 1.65 | 3,535,140 |
| 08/09/25 | 1.50 | 2.67 | 1.35 | 1.79 | 51,978,521 |
| 05/09/25 | 1.31 | 1.37 | 1.3005 | 1.33 | 7,264,198 |
| 04/09/25 | 1.33 | 1.3499 | 1.30 | 1.30 | 217,023 |
| 03/09/25 | 1.33 | 1.38 | 1.33 | 1.34 | 97,765 |
| 02/09/25 | 1.31 | 1.40 | 1.31 | 1.34 | 78,189 |
| 29/08/25 | 1.33 | 1.37 | 1.32 | 1.34 | 66,759 |
|
|
||||
|
|
||||
|
|